Your browser doesn't support javascript.
loading
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis, Maristella; Idda, Maria Laura; Lodde, Valeria; Loizedda, Annalisa; Lobina, Monia; Zoledziewska, Magdalena; Virdis, Francesca; Delogu, Giuseppe; Pirinu, Federica; Marini, Maria Giuseppina; Mingoia, Maura; Frau, Jessica; Lorefice, Lorena; Fronza, Marzia; Carmagnini, Daniele; Carta, Elisa; Orrù, Valeria; Uzzau, Sergio; Solla, Paolo; Loi, Federica; Devoto, Marcella; Steri, Maristella; Fiorillo, Edoardo; Floris, Matteo; Zarbo, Ignazio Roberto; Cocco, Eleonora; Cucca, Francesco.
Afiliação
  • Pitzalis M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Idda ML; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Lodde V; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Loizedda A; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Lobina M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Zoledziewska M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Virdis F; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Delogu G; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Pirinu F; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Marini MG; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Mingoia M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Frau J; Regional Multiple Sclerosis Center, Azienda SocioSanitaria Locale (ASSL) Cagliari, Azienda Tutela Salute (ATS) Sardegna, Cagliari, Italy.
  • Lorefice L; Regional Multiple Sclerosis Center, Azienda SocioSanitaria Locale (ASSL) Cagliari, Azienda Tutela Salute (ATS) Sardegna, Cagliari, Italy.
  • Fronza M; Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
  • Carmagnini D; Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
  • Carta E; Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
  • Orrù V; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Uzzau S; Department of Biomedical Sciences, University of Sassari - Unit of Clinical Microbiology, Azienza Ospedaliera Universitaria (AOU) Sassari, Sassari, Italy.
  • Solla P; Department of Medical, Surgical and Experimental Sciences, University of Sassari - Neurology Unit, Azienza Ospedaliera Universitaria (AOU) Sassari, Sassari, Italy.
  • Loi F; Osservatorio Epidemiologico Veterinario Regionale, Istituto Zooprofilattico Sperimentale della Sardegna, Cagliari, Italy.
  • Devoto M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Steri M; Dipartimento di Medicina Traslazionale e di Precisione, Università la Sapienza, Rome, Italy.
  • Fiorillo E; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Floris M; Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari, Italy.
  • Zarbo IR; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
  • Cocco E; Department of Medical, Surgical and Experimental Sciences, University of Sassari - Neurology Unit, Azienza Ospedaliera Universitaria (AOU) Sassari, Sassari, Italy.
  • Cucca F; Regional Multiple Sclerosis Center, Azienda SocioSanitaria Locale (ASSL) Cagliari, Azienda Tutela Salute (ATS) Sardegna, Cagliari, Italy.
Front Immunol ; 12: 781843, 2021.
Article em En | MEDLINE | ID: mdl-34956211

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antirreumáticos / Imunogenicidade da Vacina / COVID-19 / Vacina BNT162 / Esclerose Múltipla Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antirreumáticos / Imunogenicidade da Vacina / COVID-19 / Vacina BNT162 / Esclerose Múltipla Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article